As cases of chronic kidney disease emerge in outdoor laborers around the world, scientists are finding that repeated damage ...

A 6-minute walk of less than 350 meters tripled the mortality risk, whereas chronic kidney disease (CKD) independently ...

A Growing Double BurdenThe rising prevalence of prediabetes and chronic kidney disease (CKD) in India reflects an ...

Yale School of Medicine researchers have identified a biomarker panel that improves the assessment of chronic kidney disease ...

Chronic kidney disease (CKD) affects millions worldwide. It is a long-term condition where the kidneys do not work as well as ...

Finerenone (Kerendia) is thought to work by inhibiting inflammation that can cause kidney damage, according to Drugs.com. The ...

A new genetic study on the causes of chronic kidney disease that combined multiple health measurements has led to a more ...

Sending letters to encourage guideline-directed practice in the management of chronic kidney disease to either patients or their general practitioner does not improve prescription rates, shows trial.

It’s the silent, progressive disease that slowly is killing millions of Australians – but most don’t know they have it.

For patients with CKD and T2D, combination finerenone plus empagliflozin leads to a greater reduction in the urinary albumin-to-creatinine ratio than either agent alone.

Early detection and new biomarkers are changing how we manage acute kidney injury—and its link to chronic kidney disease.

Trial results offer clinically important information on the efficacy and safety of the combination therapy in CKD with type 2 diabetes.